Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.

Jason H. Lee,Jinsoo Ahn,Moon-Kyong Choi,Yong-J. Kim,Seong-Wook Hong,Kwang-Hyun Lee,I.G. Jeong,Cheryn Song,B. S. Hong,Jun Hyuk Hong,Hanjong Ahn

Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.

2014

Jason H. Lee
Jinsoo Ahn
Moon-Kyong Choi
Yong-J. Kim
Seong-Wook Hong
Kwang-Hyun Lee
I.G. Jeong
Cheryn Song
B. S. Hong
Jun Hyuk Hong
Hanjong Ahn

Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed

Keywords:

Prostate-specific antigen
Prednisolone
Colorectal cancer
Medicine
Immunology
Liver cancer
Pathology
Prostate cancer
Lung cancer
Oncology
Internal medicine
Chemotherapy
Docetaxel
Gemcitabine
GemOx
Oxaliplatin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations